济高发展: 济高发展关于公司拟向控股子公司提供财务资助的公告

Core Viewpoint - The company plans to provide financial assistance in the form of a loan not exceeding 6 million yuan to its subsidiary, Shandong Aikewei Biotechnology Co., Ltd., for operational needs, with a loan term of one year and interest rates to be determined based on prevailing bank rates and actual financing costs [1][2][7]. Financial Assistance Details - The financial assistance will not affect the company's normal business operations and funding usage [2][7]. - The loan amount is capped at 6 million yuan, with the interest rate to be negotiated at the time of signing the loan agreement [1][7]. - The financial assistance has been approved by the company's board of directors in a recent meeting [2][7]. Subsidiary Information - Aikewei Biotechnology has a registered capital of 12.31 million yuan and operates in various medical and biotechnology sectors [2]. - As of December 31, 2024, Aikewei's total assets were 672.92 million yuan, with total liabilities of 317.22 million yuan, resulting in a debt-to-asset ratio of 47.14% [3]. - The company reported a net profit loss of 7.48 million yuan for the year 2024 [3]. Related Party Transactions - The shareholder of Aikewei, Jinan High-tech Financial Investment Co., Ltd., is an affiliate of the company, and the financial assistance complies with relevant regulations [2][6]. - The company has not provided any financial assistance to Aikewei in the past 12 months, indicating no overdue financial assistance [7]. Board of Directors' Opinion - The board believes that providing financial assistance to Aikewei is beneficial for its operational needs and aligns with the company's overall strategy, ensuring that risks are manageable and compliant with legal regulations [7].